Promising Early Results for Immunotherapy-Antiangiogenesis Combination
نویسندگان
چکیده
منابع مشابه
Combination Immunotherapy for Melanoma.
Advances in precisionmedicine and immunology have led tomajor paradigmshifts in thegeneral approach to treatingpatientswith metastatic cancer. This is perhaps best exemplified by malignant melanoma, an aggressive tumor characterized by alterations in definedcell signalingpathwaysandsusceptibility to recognitionby the immunesystem.Over thepast4years, therehavebeen7newdrugs approved by the US Foo...
متن کاملIpilimumab: a promising immunotherapy for melanoma.
Antibody-based targeting of the immune suppressor molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4) with ipilimumab has been studied in metastatic melanoma in a number of clinical trials, including a recent phase III trial. This marks the first randomized clinical trial reporting an overall survival benefit using immune modulation in metastatic melanoma. Along with its therapeutic benefits, ip...
متن کاملCombination of antiangiogenesis with chemotherapy for more effective cancer treatment.
Angiogenesis is a hallmark of tumor development and metastasis and is now a validated target for cancer treatment. However, the survival benefits of antiangiogenic drugs have thus far been rather modest, stimulating interest in developing more effective ways to combine antiangiogenic drugs with established chemotherapies. This review discusses recent progress and emerging challenges in this fie...
متن کاملProstate Cancer Immunotherapy: Promising Beginnings
There has been a resurgence of interest in developing noncytotoxic immune therapies for patients with either hormone-naive biochemically relapsed post-primary therapy or castrate metastatic prostate cancer. The rationale for developing an immunotherapeutic approach has been based on the overexpression and underglycosylation of a wide variety of altered "self" molecules including prostate-specif...
متن کاملPromising role for Gc-MAF in cancer immunotherapy: from bench to bedside
Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI Journal of the National Cancer Institute
سال: 2014
ISSN: 0027-8874,1460-2105
DOI: 10.1093/jnci/dju392